Japanese professor shinya yamanaka won the first US patent in Japan for developing iPS technology
Shinya yamanaka, a professor at Kyoto university, has received a 20-year patent in the United States for his induced pluripotent stem cell (iPS) culture technique, the university announced on Tuesday. It is the first U.S. patent for a Japanese technology.
Induced pluripotent stem cells (ipscs) are item cells derived from animal somatic cells treated with inducible factors. It has similar functions to embryonic stem cells and can develop into tissues and organs. Meanwhile, it avoids the ethical and legal barriers faced by embryonic stem cell research and has a very broad prospect in the medical field.
"Obtaining a patent is important for conducting research and development with the peace of mind" Mr Yamanaka told a news conference. Research will continue in the future and hopefully contribute to clinical treatment.
Japanese media believe that the US patent, which is at the forefront of regenerative medicine, will further promote the practical research of induced pluripotent stem cell technology.
Kyoto university has applied for six patents in the United States for the basic technique of cultivating induced pluripotent stem cells, which involves the implantation of three genes into human and other animal cells, or a technology that using two genes and a protein that promotes cell proliferation to culture induced pluripotent stem cells.
So far, Kyoto university's induced pluripotent stem cell culture technology has also been patented in Europe, South Africa and Russia.
- May 16, 2019During his physical examination last year, Mr. Zhang who is 32 years old , was found to have problems such as splenomegaly, lymph node enlargement, abnormal blood routine and NK lymphocytosis, and was...view
- March 25, 2019February 22, 2019 - Cancer is a word that makes people feel scared and anxious. As a result, many women with cancer and treatment experience chronic stress and depression. Scientists have found that s...view
- June 18, 2019A new study suggests that acute myelogenous leukemia (AML) contains a rare type of cell with stem cell characteristics called "leukemia stem cells" that can predict clinical outcomes better than norma...view